Weight-Based Torsemide Dosing in Subjects With Heart Failure
Weight-Based Torsemide Dosing vs. Standard Outpatient Management in Subjects With Heart Failure: A Randomized Open-Label Pilot Study
Sponsor: New York City Health and Hospitals Corporation
This PHASE4 trial investigates Heart Failure and is currently completed. New York City Health and Hospitals Corporation leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Jan 2021 — Apr 2022 [monthly]
Recruiting PHASE4
▶ Show 7 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE4
-
Aug 2019 — Oct 2020 [monthly]
Recruiting PHASE4
-
Dec 2018 — Aug 2019 [monthly]
Recruiting PHASE4
Status: Enrolling By Invitation → Recruiting
-
Jun 2018 — Dec 2018 [monthly]
Enrolling By Invitation PHASE4
-
May 2018 — Jun 2018 [monthly]
Enrolling By Invitation PHASE4
Status: Recruiting → Enrolling By Invitation
-
Apr 2018 — May 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting · Phase: NA → PHASE4
-
Jul 2017 — Apr 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- New York City Health and Hospitals Corporation
For direct contact, visit the study record on ClinicalTrials.gov .